Last quarter (Q2 2023), OKYO Pharma's total revenue was £―, a decrease of ― from the same quarter last year. In Q2, OKYO Pharma's net income was £―. See OKYO Pharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
Total Revenue	-	-	£ 0.00	£ 0.00	£ 0.00	£ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	-	-	£ 3.01M	£ 1.21M	£ 3.48M	£ 743.93K
Operating Income	-	-	£ -3.01M	£ -1.21M	£ -3.48M	£ -743.93K
Net Non Operating Interest Income Expense	-	-	£ -858.00	£ 36.94K	£ 0.00	£ 0.00
Other Income Expense	-	-	-	-	-	-
Pretax Income	-	£ -4.55M	£ -3.02M	£ -1.27M	£ -3.76M	£ -20.17M
Tax Provision	-	£ -575.87K	£ -19.10K	£ -60.00K	£ 0.00	£ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	£ -3.98M	£ -3.00M	£ -1.21M	£ -3.76M	£ -20.17M
Basic EPS	-	-	£ >-0.01	£ >-0.01	£ -0.01	£ -0.05
Diluted EPS	-	-	£ >-0.01	£ >-0.01	£ -0.01	£ -0.05
Basic Average Shares	-	£ 979.21M	£ 672.77M	£ 595.47M	£ 513.90M	£ 382.88M
Diluted Average Shares	-	£ 979.21M	£ 672.82M	£ 595.47M	£ 513.90M	£ 382.88M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	£ 2.86K	£ 0.00
Total Expenses	-	-	£ 3.01M	£ 1.21M	£ 3.48M	£ 743.93K
Net Income From Continuing And Discontinued Operation	-	£ -3.98M	£ -3.00M	£ -1.21M	£ -3.76M	£ -20.17M
Normalized Income	-	£ -5.13M	£ -2.99M	£ -1.11M	£ -3.48M	£ -752.80K
Interest Expense	-	-	£ 858.00	£ 911.00	£ 0.00	-
EBIT	-	£ -4.55M	£ -3.02M	£ -1.27M	£ -3.76M	£ -743.93K
EBITDA	-	-	£ -3.01M	£ -1.27M	£ -3.76M	£ -743.93K

Currency in GBP

OKYO Pharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing